More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.01B
EPS
-0.64
P/E ratio
--
Price to sales
2.81
Dividend yield
--
Beta
0.995316
Previous close
$32.65
Today's open
$32.32
Day's range
$31.99 - $33.21
52 week range
$17.72 - $44.28
show more
CEO
Derek J. Maetzold
Employees
761
Headquarters
Friendswood, TX
Exchange
NASDAQ Global Market
Shares outstanding
30549507
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Aug 28, 2026

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Aug 25, 2026

Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.
PRNewsWire • Aug 20, 2026

Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.
PRNewsWire • Aug 17, 2026

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
MarketBeat • Aug 13, 2026

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Seeking Alpha • Jul 31, 2026

Castle Biosciences Q2 Earnings Call Highlights
Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
MarketBeat • Jul 30, 2026

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $0.15 per share a year ago.
Zacks Investment Research • Jul 30, 2026

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.
PRNewsWire • Jul 22, 2026

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis FRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).
PRNewsWire • Jul 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Castle Biosciences, Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.